Researchers Discover Critical Role of Hydrogen Sulfide in Ability of Bacteria to Survive Antibiotics

NEW YORK, June 10, 2021 /PRNewswire/ -- The signaling molecule hydrogen sulfide (H₂S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.

Published online in the journal Science on June 11, the study revolves around tolerance, wherein bacteria in general have evolved to use common defense systems to resist antibiotics. Tolerance differs from antibiotic resistance, where one species happens to acquire a genetic change that helps them resist treatment.

In one defense mechanism, tolerant bacteria, also called "persisters," stop multiplying (proliferating), reducing their energy use (metabolism) to survive antibiotic treatment, but resuming growth when the treatment ends. Persisters are particularly abundant in biofilms, bacterial colonies that live in tough polymeric matrices which further prevent their eradication.

"The combined trends toward resistant infections and fewer new antimicrobials are projected to kill 10 million people annually by the year 2050," says corresponding study author Evgeny Nudler, PhD, the Julie Wilson Anderson Professor of Biochemistry at NYU Langone Health, and an investigator with the Howard Hughes Medical Institute. "New approaches are urgently needed to prevent this, and our study suggests that suppressing bacterial H₂S would make different antibiotics more potent."

In their prior work, the NYU Langone research team showed that H₂S production is deployed against antibiotics by a wide variety of bacterial species, including two increasingly antibiotic-resistant pathogens prevalent in hospital-borne infections: Staphylococcus aureus and Pseudomonas aeruginosa. S. aureus is gram-positive, while Pseudomonas aeruginosa is gram-negative, with the differing organizations of their outer layers demonstrating that H₂S production protects pathogens across the bacterial kingdom.

Remarkably, the research team found that both species rely on the same enzyme, cystathionine γ-lyase (CSE), for the bulk of H₂S production. Blocking its action would represent then a way to remove an important defense against antibiotics, but available CSE inhibitors have a low potency against bacterial CSE and a high probability of causing side effects in human tissue, says Nudler.

To find better inhibitors, the research team obtained an x-ray structure of S. aureus CSE and used it to "virtually screen" millions of drug-like compounds looking for those with the right shape and properties to block the enzyme's action without side effects. The team selected lead compounds, NL1, NL2, and NL3, which inhibited the bacterial CSE, blocked H₂S production by both S. aureus and P. aeruginosa, and strengthened the effect of bactericidal antibiotics from different classes. Furthermore, NL1 increased the potency of antibiotic effect in mouse models of S. aureus and P. aeruginosa infection.

Unexpectedly, further testing revealed that the NL compounds markedly diminished persisters, and suppressed biofilm formation in both pathogens. 

How exactly H₂S contributes to tolerance remains to be established, but there are some hints.

"Bacteria appear to use controlled, self-poisoning with H₂S to slow down their metabolism, preventing the antibiotics from using the bacteria's energy production system to kill them," says Nudler. "Interfering with the H₂S-based defenses represents a largely unexplored alternative to the traditional antibiotic discovery. Our results suggest that a new kind of small molecule potentiator can strengthen the effect of major classes of clinically important antibiotics."

The authors note several opportunities for designing conceptually novel antimicrobial therapeutics by combining H₂S-blocking potentiators with antibiotics. Such combinations may have better efficacy against bacterial biofilms. Other potential applications include overcoming intermediate-level antibiotic resistance; reducing antibiotic dose and related toxicity while maintaining efficacy; and enhancing the bacteria-killing (bactericidal) effect at the same antibiotic dose.

Along with Nudler, the study was led by first authors Konstantin Shatalin and Ashok Nuthanakanti in the Department of Biochemistry and Molecular Pharmacology at NYU Langone Health. Also authors were Abhishek Kaushik, Alla Peselis, Ilya Shamovsky, Bibhusita Pani, Mirna Lechpammer, Nikita Vasiliev, Elena Shatalina, and Alexander Serganov at NYU Langone, as well as Dmitry Shishov and Peter Fedichev of Gero LLC, Moscow, Russia; Dmitri Rebatchouk of Ellyris LLC in Union, NJ; and Alexander Mironov of the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences in Moscow. The study was funded by the Blavatnik Family Foundation, the United States Department of Defense, and the Howard Hughes Medical Institute.

CONTACT: Gregory Williams, [email protected]

SOURCE NYU Grossman School of Medicine